Baba Inusa

4.6k total citations
117 papers, 1.9k citations indexed

About

Baba Inusa is a scholar working on Genetics, Hematology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Baba Inusa has authored 117 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 108 papers in Genetics, 79 papers in Hematology and 30 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Baba Inusa's work include Hemoglobinopathies and Related Disorders (108 papers), Iron Metabolism and Disorders (72 papers) and Blood groups and transfusion (19 papers). Baba Inusa is often cited by papers focused on Hemoglobinopathies and Related Disorders (108 papers), Iron Metabolism and Disorders (72 papers) and Blood groups and transfusion (19 papers). Baba Inusa collaborates with scholars based in United Kingdom, United States and Italy. Baba Inusa's co-authors include Stephen Obaro, Catherine Booth, Fenella J. Kirkham, David C. Rees, Michael R. DeBaun, Jo Howard, Kofi A. Anie, Wale Atoyebi, Mark Rodeghier and Lewis L. Hsu and has published in prestigious journals such as New England Journal of Medicine, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Baba Inusa

110 papers receiving 1.8k citations

Peers

Countries citing papers authored by Baba Inusa

Since Specialization

Citations

This map shows the geographic impact of Baba Inusa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Baba Inusa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Baba Inusa more than expected).

Fields of papers citing papers by Baba Inusa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Baba Inusa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Baba Inusa. The network helps show where Baba Inusa may publish in the future.

Co-authorship network of co-authors of Baba Inusa

This figure shows the co-authorship network connecting the top 25 collaborators of Baba Inusa. A scholar is included among the top collaborators of Baba Inusa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Baba Inusa. Baba Inusa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Treating sickle cell disease in resource-limited sub-Saharan Africa: recent strategies and recommendations in addressing the gaps for the provision of evidence-based management 2025 ·Expert Review of Hematology ·Miguel Brito, (unknown), Akinyemi O D Ofakunrin, (unknown), Baba Inusa	1
2	Sickle Cell Health Awareness, Perspectives, and Experiences (SHAPE) survey: Perspectives of adolescent and adult patients, caregivers, and healthcare professionals on the burden of sickle cell disease 2024 ·European Journal Of Haematology ·Mariane de Montalembert, (unknown), Fernando Ferreira Costa, Baba Inusa, Wasil Jastaniah, Joachim B. Kunz, (unknown), (unknown), John S James, (unknown), Anne Beaubrun, Bélinda Lartey, Isaac Odame	2
3	Efficacy, safety, and pharmacokinetics of a new, ready-to-use, liquid hydroxyurea in children with sickle cell anemia 2023 ·Blood Advances ·Angela Rankine‐Mullings, Russell Keenan, Subarna Chakravorty, Baba Inusa, Paul Telfer, Mark Velangi, Russell E. Ware, (unknown), (unknown), Sarah Edwards, Hussain Mulla	5
4	Global burden of transfusion in sickle cell disease 2023 ·Transfusion and Apheresis Science ·Baba Inusa, Wale Atoyebi, Biree Andemariam, (unknown), Laurel Omert	6
5	Deferiprone versus deferoxamine for transfusional iron overload in sickle cell disease and other anemias: Pediatric subgroup analysis of the randomized, open‐label FIRST study 2023 ·Pediatric Blood & Cancer ·Mona Hamdy, Amal El‐Beshlawy, (unknown), Julie Kanter, Baba Inusa, Suzan Williams, David Lee, (unknown), Caroline Fradette, Fernando Tricta, Fatma Soliman Elsayed Ebeid, Janet L. Kwiatkowski, Mohsen Saleh Elalfy	4
6	Ticagrelor vs placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: the HESTIA3 study 2022 ·Blood ·Matthew M. Heeney, Miguel R. Abboud, Jessie Githanga, Baba Inusa, Julie Kanter, Alan D. Michelson, Videlis Nduba, Victor Musiime, (unknown), Adlette Inati, Amar Taksande, Marielle Andersson, Magnus Åstrand, Noha Maklad, Mohammad Niazi, Anders Himmelmänn, Anders Berggren	11
7	Safety and efficacy of voxelotor in pediatric patients with sickle cell disease aged 4 to 11 years 2022 ·Pediatric Blood & Cancer ·Jeremie H. Estepp, Ram Kalpatthi, Gerald M. Woods, Sara Trompeter, Robert I. Liem, (unknown), Adlette Inati, Baba Inusa, Andrew Campbell, Connie M. Piccone, Miguel R. Abboud, Kim Smith‐Whitley, (unknown), Margaret Tonda, Carla Washington, Noelle M. Griffin, R. Clark Brown	31
8	Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years 2022 ·Blood Advances ·Mohsen Saleh Elalfy, Mona Hamdy, Amal El‐Beshlawy, Fatma Soliman Elsayed Ebeid, Mohamed Badr, Julie Kanter, Baba Inusa, Amira Adly, Suzan Williams, Yurdanur Kılınç, David D. Lee, Caroline Fradette, (unknown), (unknown), Fernando Tricta, Janet L. Kwiatkowski	16
9	Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study 2021 ·Blood Advances ·Janet L. Kwiatkowski, Mona Hamdy, Amal El‐Beshlawy, Fatma Soliman Elsayed Ebeid, (unknown), Abdulrahman Alshehri, Julie Kanter, Baba Inusa, Amira Adly, Suzan Williams, Yurdanur Kılınç, David Lee, Fernando Tricta, Mohsen Saleh Elalfy	33
10	Genetic Analysis of Patients With Sickle Cell Anemia and Stroke Before 4 Years of Age Suggest an Important Role for Apoliprotein E 2020 ·Circulation Genomic and Precision Medicine ·John Brewin, Alexander Smith, (unknown), Sanjay Tewari, (unknown), Sarah Wilkinson, Valentine Brousse, Baba Inusa, Stephan Menzel, David C. Rees	8
11	COVID‐19 and the pulmonary complications of sickle cell disease 2020 ·SHILAP Revista de lepidopterología ·(unknown), Baba Inusa, Pat Doyle, Eugene Oteng‐Ntim	13
12	Beneficial effects of adenotonsillectomy in children with sickle cell disease 2020 ·ERJ Open Research ·Ilaria Liguoro, Michele Arigliani, (unknown), (unknown), Subarna Chakravorty, Cara Bossley, (unknown), David C. Rees, Baba Inusa, Atul Gupta	4
13	Symptoms and Complications of Sickle Cell Disease Analyzed By Patient-Reported Genotype, Sex and Country/Region: Results from the International Sickle Cell World Assessment Survey (SWAY) 2020 ·Baba Inusa	1
14	An Educational Study Promoting the Delivery of Transcranial Doppler Ultrasound Screening in Paediatric Sickle Cell Disease: A European Multi-Centre Perspective 2019 ·Journal of Clinical Medicine ·Baba Inusa, Laura Sainati, (unknown), Raffaella Colombatti, Maddalena Casale, Silverio Perrotta, (unknown), Claire Hemmaway, Soundrie Padayachee	11
15	Sickle Cell Disease—Genetics, Pathophysiology, Clinical Presentation and Treatment 2019 ·International Journal of Neonatal Screening ·Baba Inusa, Lewis L. Hsu, Neeraj Kohli, (unknown), (unknown), Kofi A. Anie, Wale Atoyebi	127
16	Utilising the ‘Getting to Outcomes®’ Framework in Community Engagement for Development and Implementation of Sickle Cell Disease Newborn Screening in Kaduna State, Nigeria 2018 ·International Journal of Neonatal Screening ·Baba Inusa, Kofi A. Anie, Andrea Lamont, (unknown), (unknown), (unknown), Wale Atoyebi, (unknown), (unknown), Lewis L. Hsu	6
17	Prevention of Morbidity in Sickle Cell Disease Phase II (Improvement of Pain and Quality of Life in Children with Sickle Cell Disease with Auto-adjusting Continuous Positive Airways Pressure: Phase II) (POMS 2b pediatric cohort) 2017 ·Blood ·April Slee, Jamie M. Kawadler, (unknown), (unknown), David C. Rees, (unknown), Jo Howard, Swee Lay Thein, Simon S. Skene, (unknown), (unknown), (unknown), Dawn E. Saunders, Johanna Gavlak, (unknown), (unknown), Christina Liossi, Fenella J. Kirkham, Baba Inusa	4
18	Juvenile polymyositis with unremitting pain and progressive loss of motor and bulbar function on a background of sickle cell disease 2015 ·BMJ Case Reports ·(unknown), David D’Cruz, (unknown), Baba Inusa	4
19	Moving young people with sickle cell disease from paediatric to adult services 2010 ·British Journal of Hospital Medicine ·Jo Howard, (unknown), (unknown), (unknown), Baba Inusa	9
20	Risk Factors for Stroke Recurrence in Sickle Cell Disease 2009 ·UCL Discovery (University College London) ·Fenella J. Kirkham, Nomazulu Dlamini, (unknown), D. Saunders, (unknown), Kyuha Chong, (unknown), (unknown), Anne Yardumian, Jane Porter, Paul Telfer, (unknown), (unknown), David Rees, Susan E. Height, Moira Dick, (unknown), (unknown), I Roberts, Baba Inusa	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact